Systems for delivery and release of angiotensin-(1-7)
CA 2466232 C · Owner: Universidade Federal De Minas Gerais-Ufmg · Inventors: Nadu, Ana Paula; Millan, Ruben Dario Sinisterra; Dos Santos, Robson Augusto Souza
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
There is no description in the state of technique of a formulation application or product of D-Ala7-Angiotensin-(1-7) (A-779) and analogues and derivatives, D-Pro7-Angiotensin-(1-7) and analogues or derivatives or of Ang- (1-7) analogues or derivatives using ciclodextrines lipossomes, biodegradable , polymers and its derivatives for the study or treatment of arterial hypertension and other cardiovascular diseases and its complications wounds, burns, erithema, tumors, diabetes mellitus sperm mobility, nephropathy, gastrointestinal and gynaecological disorders angiogenesis, angioplatsy, alopecia and blood diseases in animals of warm blood or as ligands for de G-, protein-coupled receptor …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 5, 2002 and granted July 14, 2015. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 5, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 5, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.